Devyser Diagnostics AB (publ) (STO:DVYSR)

Sweden flag Sweden · Delayed Price · Currency is SEK
93.20
-2.70 (-2.82%)
Apr 28, 2026, 5:29 PM CET
-4.61%
Market Cap 1.61B
Revenue (ttm) 257.50M
Net Income (ttm) 15.00M
Shares Out 16.79M
EPS (ttm) 0.89
PE Ratio 107.18
Forward PE 32.16
Dividend n/a
Ex-Dividend Date n/a
Volume 287,162
Average Volume 51,665
Open 96.00
Previous Close 95.90
Day's Range 90.10 - 96.60
52-Week Range 74.00 - 159.60
Beta 0.71
RSI 74.41
Earnings Date Apr 27, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the inter... [Read more]

Sector Healthcare
Founded 2004
Employees 116
Stock Exchange Nasdaq Stockholm
Ticker Symbol DVYSR
Full Company Profile

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.

Financial Statements

News

There is no news available yet.